Status:
COMPLETED
Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.
Lead Sponsor:
Pfizer
Conditions:
Hypercholesterolemia, Familial
Hyperlipidemia
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with...
Detailed Description
For additional information please call: 1-800-718-1021
Eligibility Criteria
Inclusion
- Diagnosis of Heterozygous Familial Hypercholesterolemia
- At least 18 years of age
Exclusion
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid (high doses)
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT00136981
Start Date
December 1 2003
End Date
November 1 2006
Last Update
April 22 2015
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Hartford, Connecticut, United States
2
Pfizer Investigational Site
Boston, Massachusetts, United States
3
Pfizer Investigational Site
Minneapolis, Minnesota, United States
4
Pfizer Investigational Site
New York, New York, United States